Alastair Garfield
Known title: Chief Scientific OfficerCIK: 0002027261
Associated companies
Transaction History
| RYTM | ▼ Sell | Open Market | 2,007 | $233K | 8/13/2026 | View on chart |
| RYTM | ▼ Sell | Open Market | 1,556 | $182K | 8/13/2026 | View on chart |
| RYTM | ▼ Sell | Open Market | 3,400 | $402K | 8/13/2026 | View on chart |
| RYTM | ▼ Sell | Open Market | 800 | $95K | 8/13/2026 | View on chart |
| RYTM | ▲ Buy | Option Exercise | 4,445 | — | 7/1/2026 | View on chart |
| RYTM | ▼ Sell | Tax Withholding | 2,150 | $237K | 7/1/2026 | View on chart |
| RYTM | ▲ Buy | Option Exercise | 6,663 | — | 2/1/2026 | View on chart |
| RYTM | ▼ Sell | Tax Withholding | 2,026 | $221K | 2/1/2026 | View on chart |
| RYTM | ▼ Sell | Open Market | 1,313 | $85K | 7/2/2025 | View on chart |
| RYTM | ▼ Sell | Open Market | 6 | $388 | 7/2/2025 | View on chart |
| RYTM | ▲ Buy | Option Exercise | 4,445 | — | 7/1/2025 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 9, 2026
RYTM: RBC raises price target to $159, maintains Outperform
RBC Capital kept its Outperform rating on Rhythm Pharmaceuticals and lifted its price target to $159. The new target sits well above the stock’s 52‑week high of $122.20 and higher than the consensus analyst target of $138.59. A recent Benzinga piece also highlighted the stock’s five‑year total return, underscoring its past performance. These developments may influence market perception of the company’s growth prospects.
RYTM: RBC raises price target to $159, maintains Outperform. RBC Capital kept its Outperform rating on Rhythm Pharmaceuticals and lifted its price target to $159. The new target sits well above the stock’s 52‑week high of $122.20 and higher than the consensus analyst target of $138.59. A recent Benzinga piece also highlighted the stock’s five‑year total return, underscoring its past performance. These developments may influence market perception of the company’s growth prospects.